Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$259.94M+682236.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael S. Weiss
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 399
- Beta
- 1.81
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 6.58
Financials
Revenue
$259.94M+682236.3%Net Income
$55.46MEBITDA
$89.75MFree Cash Flow
$44.95MEPS (diluted)
$0.35Shares Outstanding (diluted)
155.93M+216.4%Operating Expenses
$131.96MCash & Debt
$504.67MReturn of Capital
$100.00MRevenue by Segment (annual)
$616.29MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $616.29M | $447.18M | $3.10 |
| 2024 | $329.00M | $23.38M | $0.16 |
| 2023 | $233.66M | $12.67M | $0.09 |
| 2022 | $2.79M | $-223.81M | $-1.46 |
| 2021 | $6.69M | $-348.10M | $-2.63 |
| 2020 | $152.0K | $-279.38M | $-2.42 |
| 2019 | $152.0K | $-172.87M | $-1.96 |
| 2018 | $152.0K | $-173.48M | $-2.30 |
| 2017 | $152.4K | $-118.48M | $-1.91 |
| 2016 | $152.4K | $-78.25M | $-1.60 |
| 2015 | $152.4K | $-62.95M | $-1.38 |
| 2014 | $152.4K | $-55.78M | $-1.64 |
| 2013 | $152.4K | $-20.48M | $-0.81 |
| 2012 | $19.0K | $-18.07M | $-1.38 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $4.55
- Implied price
- $45.53
- Return from $65.16
- -6.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $22.64 — -65.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 6 | 8 | 10 | 12 | 14 |
|---|---|---|---|---|---|
| -2.0% | -23.7% | -19.2% | -15.5% | -12.4% | -9.7% |
| 3.0% | -19.9% | -15.1% | -11.2% | -7.9% | -5.0% |
| 8.0% | -16.0% | -11.0% | -6.9% | -3.5% | -0.4% |
| 13.0% | -12.1% | -6.9% | -2.6% | 1.0% | 4.2% |
| 18.0% | -8.2% | -2.7% | 1.7% | 5.5% | 8.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-37.50%Social Signal Score
Mentions (22)
- Newsbusinesswire.com·4d ago·Neutral
TG Therapeutics Ranked Number 5 Fastest-Growing Company in North America on the 2026 Deloitte Technology Fast 500™ NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number 5 on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 32nd year.The Company's growth between fiscal years 2022 to 2025 was fueled by BR…
View source ↗ - News (RSS)fool·7d ago·Positive
TG Therapeutics: 3 Key Takeaways for Long-Term Investors Single-dose IV initiation could remove a second clinic visit, but it remains to be seen whether that convenience translates into demand before 2027.
View source ↗ - Newsfool.com·8d ago·Positive
TG Therapeutics: 3 Key Takeaways for Long-Term Investors TG Therapeutics raised full-year 2026 global revenue guidance to $1 billion. Subcutaneous BRIUMVI could more than double peak sales opportunity.
View source ↗ - Newszacks.com·12d ago·Positive
TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up TG Therapeutics beats Q3 earnings and revenue estimates as Briumvi demand accelerates, shares rise 5.9%, and 2026 revenue guidance climbs to $1 billion.
View source ↗ - Newsseekingalpha.com·13d ago·Positive
TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call Transcript TG Therapeutics, Inc. ( TGTX ) Q3 2026 Earnings Call November 9, 2026 8:30 AM EST Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO & President Adam Waldman - Chief Commercialization Officer Sean Power - CFO, Corporate Secretary & Treasurer Conference Call Participants Michael DiFiore - Evercore ISI Institutional Equities, Research Division Tara Bancroft - TD Cowen, Rese…
View source ↗ - Newsmarketbeat.com·13d ago·Positive
What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call TG Therapeutics NASDAQ: TGTX raised its 2026 revenue outlook after third-quarter sales of its multiple sclerosis treatment BRIUMVI climbed 52% in the United States, and executives said they expect a stronger fourth quarter.
View source ↗ - Newszacks.com·13d ago·Neutral
TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newsbusinesswire.com·20d ago·Neutral
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 9, 2026, at 8:30 AM ET to discuss results for the third quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, p…
View source ↗ - Newszacks.com·27d ago·Neutral
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - News (RSS)investing·30d ago·Neutral
TG Therapeutics reports phase 1 MS trial results for azer-cel
View source ↗ - News (Marketaux)gurufocus.com·32d ago·Positive
TG Therapeutics (TGTX) Showcases Long-Term MS Trial Data and Advances at ACTRIMS-ECTRIMS 2026 On October 21, 2026, TG The[+290 characters]
View source ↗ - Newszacks.com·40d ago·Positive
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know TG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.
View source ↗ - Newsbusinesswire.com·41d ago·Neutral
…s Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression outcomes with BRIUMVI® (ublituximab-xiiy) compared with ocrelizumab and ofatumumab in patients with relapsing multiple s…
View source ↗ - Newsbusinesswire.com·45d ago·Negative
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, 2026, in Toronto, Canada. The presentations include a late-breaking oral presentation highlighting initial results from a Phase 1 study evaluating azer-cel in patients with primary progressive…
View source ↗ - Newsmarketbeat.com·65d ago·Neutral
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share TG Therapeutics NASDAQ: TGTX Chairman, President and Chief Executive Officer Mike Weiss said the company's multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market.
View source ↗ - News (RSS)yahoo·81d ago·Positive
IBD Stock Of The Day, TG Therapeutics, Eyes Breakout After Topping Early Buy Point
View source ↗ - Newszacks.com·81d ago·Neutral
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue? TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsseekingalpha.com·88d ago·Positive
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade) TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.
View source ↗ - News (RSS)yahoo·90d ago·Positive
TGTX Stock Outperforms 95% of Stocks. Here's Why.
View source ↗ - News (RSS)seekingalpha·92d ago·Positive
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
View source ↗ - Newsseekingalpha.com·92d ago·Positive
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes.
View source ↗ - News (RSS)yahoo·93d ago·Neutral
TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.56 per share
Typical surprise -46.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$0.35 vs $0.36miss
- Mon, Aug 3$0.05 vs $0.31miss
- Wed, May 6$0.14 vs $0.23miss
- Thu, Feb 26$0.14 vs $0.35miss
- Mon, Nov 3$2.43 vs $0.24beat
- Mon, Aug 4$0.17 vs $0.32miss
Estimates and results for TGTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TGTX officers and directors.
- Bought
- $1.1m
- Sold
- $16.8m
2 trades
24 trades
- Charney Laurence Nsold
- Echelard Yannsold
- Lonial Sagarsold
- Echelard Yannsold
- Power Sean Asold
- Power Sean Asold
- Lonial Sagarsold
- Charney Laurence Nsold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Nov 6, 2020 (59d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
